Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Deferred Tax Liability (2018 - 2024)

Historic Non-Current Deferred Tax Liability for Ptc Therapeutics (PTCT) over the last 7 years, with Q3 2024 value amounting to $55.9 million.

  • Ptc Therapeutics' Non-Current Deferred Tax Liability rose 766.85% to $55.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $55.9 million, marking a year-over-year increase of 766.85%. This contributed to the annual value of $55.9 million for FY2023, which is 4563.57% down from last year.
  • As of Q3 2024, Ptc Therapeutics' Non-Current Deferred Tax Liability stood at $55.9 million, which was up 766.85% from $55.9 million recorded in Q2 2024.
  • Ptc Therapeutics' Non-Current Deferred Tax Liability's 5-year high stood at $137.1 million during Q4 2021, with a 5-year trough of $51.9 million in Q3 2023.
  • For the 5-year period, Ptc Therapeutics' Non-Current Deferred Tax Liability averaged around $106.4 million, with its median value being $130.9 million (2020).
  • In the last 5 years, Ptc Therapeutics' Non-Current Deferred Tax Liability plummeted by 6212.75% in 2023 and then skyrocketed by 767.02% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $136.7 million in 2020, then rose by 0.27% to $137.1 million in 2021, then decreased by 25.0% to $102.8 million in 2022, then tumbled by 45.64% to $55.9 million in 2023, then grew by 0.01% to $55.9 million in 2024.
  • Its last three reported values are $55.9 million in Q3 2024, $55.9 million for Q2 2024, and $55.9 million during Q1 2024.